BME103 s2013:TEMPwu3: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
Line 188: Line 188:
'''DESIGN'''
'''DESIGN'''


<!-- If your team decided to only amplify cancer-associated DNA, list the Cancer allele forward primer and the Cancer allele reverse primer. Include a paragraph that explains why a disease allele will give a PCR product and the non-disease allele will not.-->
 
'''Primers for PCR'''<br>
<!-- If your team decided to only amplify cancer-associated DNA, list the "Cancer allele forward primer" sequence and the "Cancer allele reverse primer" sequence. Include a paragraph that explains why a disease allele will give a PCR product and the non-disease allele will not.-->


<!-- If your team chose an alternative approach to amplify the DNA, list all relevant primers. Include a paragraph that explains how your system works.-->
<!-- If your team chose an alternative approach to amplify the DNA, list all relevant primers. Include a paragraph that explains how your system works.-->
Line 196: Line 198:
* Design specification 2 - explanation of how an aspect of the primers addresses any of the specifications in the "New System: Design Strategy" section
* Design specification 2 - explanation of how an aspect of the primers addresses any of the specifications in the "New System: Design Strategy" section
* Etc.
* Etc.
'''Illustration'''
<!--- Include an illustration that shows how your system's primers allow specific amplification of the disease-related SNP --->





Revision as of 18:09, 9 April 2013

BME 103 Spring 2013 Home
People
Lab Write-Up 1
Lab Write-Up 2
Lab Write-Up 3
Course Logistics For Instructors
Photos
Wiki Editing Help

OUR TEAM

Name: Student
Role(s)
Name: Student
Role(s)
Name: Student
Role(s)
Name: Student
Role(s)
Name: Student
Role(s)

LAB 3 WRITE-UP

Original System: PCR Results

PCR Test Results

Sample Name ng/mL Conclusion (pos/neg)
Positive Control --- N/A
Negative Control --- N/A
Tube Label:___ Patient ID: ____ rep 1 ---
Tube Label:___ Patient ID: ____ rep 2 ---
Tube Label:___ Patient ID: ____ rep 3 ---
Tube Label:___ Patient ID: ____ rep 1 ---
Tube Label:___ Patient ID: ____ rep 2 ---
Tube Label:___ Patient ID: ____ rep 3 ---


Bayesian Statistics
These statistics are based upon all of the DNA detection system results that were obtained in the PCR lab for 34 hypothetical patients who were diagnosed as either having cancer or not having cancer.

Bayes Theorem equation: P(A|B) = P(B|A) * P(A) / P(B)


Calculation 1: The probability that the sample actually has the cancer DNA sequence, given a positive diagnostic signal.

  • A = [text description] = [frequency shown as a fraction] = [final numerical value]
  • B = [text description] = [frequency shown as a fraction] = [final numerical value]
  • P (B|A) = [text description] = [frequency shown as a fraction] = [final numerical value]
  • P(A|B) = [answer]



Calculation 3: The probability that the patient will develop cancer, given a cancer DNA sequence.

  • A = [text description] = [frequency shown as a fraction] = [final numerical value]
  • B = [text description] = [frequency shown as a fraction] = [final numerical value]
  • P (B|A) = [text description] = [frequency shown as a fraction] = [final numerical value]
  • P(A|B) = [answer]



New System: Design Strategy

We concluded that a good system Must Have:

  • [Must have #1 - why? short, ~4 or 5 sentences]
  • [Must have #2 - why? short, ~4 or 5 sentences]


We concluded that we would Want a good system to have:

  • [Want #1 - why? short, ~4 or 5 sentences]
  • [Want #2 - why? short, ~4 or 5 sentences]


We concluded that a good system Must Not Have:

  • [Must Not Have #1 - why? short, ~4 or 5 sentences]
  • [Must Not Have #2 - why? short, ~4 or 5 sentences]


We concluded that a good system Should Avoid:

  • [Should Avoid #1 - why? short, ~4 or 5 sentences]
  • [Should Avoid #2 - why? short, ~4 or 5 sentences]




New System: Machine/ Device Engineering

SYSTEM DESIGN


KEY FEATURES

We chose to include these new features

  • Feature 1 - explanation of how this addresses any of the specifications in the "New System: Design Strategy" section
  • Feature 2 - explanation of how this addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.

[OR]

We chose keep the devices the same as the original system

  • Feature 1 - explanation of how a pre-existing feature addresses any of the specifications in the "New System: Design Strategy" section
  • Feature 2 - explanation of how a pre-existing feature addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.


INSTRUCTIONS





New System: Protocols

DESIGN AND MATERIALS

We chose to include these new approaches/ features

  • Feature 1 - explanation of how this addresses any of the specifications in the "New System: Design Strategy" section
  • Feature 2 - explanation of how this addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.

[OR]

We chose keep the protocols the same as the original system

  • Feature 1 - explanation of how a pre-existing feature addresses any of the specifications in the "New System: Design Strategy" section
  • Feature 2 - explanation of how a pre-existing feature addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.

MATERIALS


PROTOCOLS

  • PCR Protocol
  • DNA Measurement and Analysis Protocol


New System: Research and Development

BACKGROUND


DESIGN


Primers for PCR


Our primers address the following design needs

  • Design specification 1 - explanation of how an aspect of the primers addresses any of the specifications in the "New System: Design Strategy" section
  • Design specification 2 - explanation of how an aspect of the primers addresses any of the specifications in the "New System: Design Strategy" section
  • Etc.